We are live on ! Find out more
TPC

Takeda Pharmaceutical Company Portfolio holdings

AUM $16.4M
1-Year Est. Return 195.92%
This Fund
S&P 500
This Quarter Est. Return
+0.32%
1 Year Est. Return
+195.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$26.6M
AUM Growth
-$11.4M
Cap. Flow
-$9.77M
Cap. Flow %
-36.78%
Top 10 Hldgs %
99.89%
Holding
12
New
2
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$816K
2
THRD
Third Harmonic Bio
THRD
+$459K

Top Sells

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$13.9M 52.4%
6,724,000
– –
OVID icon
2
Ovid Therapeutics
OVID
$489M
$7.01M 26.4%
7,531,996
– –
XLO icon
3
Xilio Therapeutics
XLO
$59.9M
$1.42M 5.33%
105,366
– –
EQ icon
4
Equillium
EQ
$138M
$1.37M 5.15%
1,824,977
– –
STTK icon
5
Shattuck Labs
STTK
$704M
$624K 2.35%
515,619
– –
AMWL icon
6
American Well
AMWL
$221M
$564K 2.12%
77,733
– –
LYEL icon
7
Lyell Immunopharma
LYEL
$330M
$527K 1.98%
+41,166
New +$816K
TSBX
8
DELISTED
Turnstone Biologics
TSBX
$448K 1.69%
895,824
– –
THRD
9
DELISTED
Third Harmonic Bio
THRD
$379K 1.43%
+36,835
New +$459K
RANI icon
10
Rani Therapeutics
RANI
$87.7M
$278K 1.05%
203,190
– –
LAB icon
11
Standard BioTools
LAB
$307M
$28.9K 0.11%
16,515
– –
WVE icon
12
Wave Life Sciences
WVE
$1.17B
– –
-1,346,892
Closed -$11M

Similar funds

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DADR
Dynamo Administracao de Recursos Rio De Janeiro, Brazil $18.5M AUM 37.41% 1-Year Est. Return
AVM
Avalon Ventures Management La Jolla, California $14.2M AUM 9.35% 1-Year Est. Return
RCMU
Rokos Capital Management (US) New York $14.2M AUM
PM
Pharo Management New York $18.7M AUM
SHM
Sagard Holdings Management Toronto, Ontario, Canada $20M AUM
SI
SQN Investors Menlo Park, California $12.8M AUM

Takeda Pharmaceutical Company's Q4 2024 Portfolio in Review

As of Q4 2024, Takeda Pharmaceutical Company held 12 positions worth $26.6M, down 30% from $38M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Takeda Pharmaceutical Company withdrew a net $9.77M in Q4 2024, closing 1 position. Its most notable exit was Wave Life Sciences, an estimated $11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Takeda Pharmaceutical Company opened a new position in Lyell Immunopharma worth $527K.

  • Takeda Pharmaceutical Company's largest Q4 2024 buy was Lyell Immunopharma: 41,166 shares worth $527K.
  • Takeda Pharmaceutical Company fully exited Wave Life Sciences in Q4 2024, selling an estimated $11M.
  • Takeda Pharmaceutical Company's ten largest holdings make up 100% of its $26.6M portfolio in Q4 2024.
  • Takeda Pharmaceutical Company opened 2 new positions and closed 1 in Q4 2024.
  • Takeda Pharmaceutical Company's portfolio value fell 30% quarter-over-quarter to $26.6M.

Based on Takeda Pharmaceutical Company's 13F filing for Q4 2024, filed 12 Feb 2025.